DRUG DEVELOPMENT – Advancing Personalized Medicine: A Seamless Solution to Discover & Deliver Novel Diagnostic Tests
The use of companion diagnostics in conjunction with custom pharmaceuticals is expected to expand as the promise of personalized medicine continues to be realized. However, a concurrent development cycle of both diagnostic and therapeutic requires a complex synergy of both diagnostic and drug development, and represents a significant deviation from the current pharmaceutical model.
Dr. Marc Mansour, Chief Operating Officer & Chief Science Officer of Immunovaccine, discusses the DepoVax platform and the companyâ€™s clinical trials for DPX-0907 and DPX-Survivac.
EXECUTIVE INTERVIEW – NanoSmart Pharmaceuticals: Patented Delivery Platform Using Human Autoimmune Antibodies to Target Cancers & Other Debilitating Diseases
Dr. James Smith, President of NanoSmart Pharmaceuticals, discusses his company’s innovative approach to drug delivery using immunoliposomes and their unique targeting ability.
FORMULATION DEVELOPMENT – Oral Administration of an Insulin-Soybean Suspension in Streptozocin Rats: Effect of Aqueous Soybean Extract Vehicle
Antoine Al-Achi, PhD; Brijesh Patel, MS; and Sejal Patel, MS; investigate in this study the hypoglycemic activity of an insulin suspension given orally in a vehicle of soybean extract to streptozocin diabetic rats.
BIOAVAILABILITY ENHANCEMENT – A Novel Spray-Drying Technology to Improve the Bioavailability of Biopharmaceutical Classification System Class II Molecules
David Shi, PhD; Andrew Loxley, PhD; Robert W. Lee, PhD; and David Fairhurst, PhD; briefly discuss a proven and scalable solid dispersion approach based on spray-drying that is suitable for BCS Class II APIs and NCEs.
EXCLUSIVE ONLINE CONTENT
Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies
The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.
Loxo Oncology, Inc. recently entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd.
Aclaris Therapeutics, Inc. recently announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness.
iBio, Inc. recently announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.
Gilead Sciences, Inc. and Nurix Therapeutics, Inc. recently announced a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.